Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Maternity
  4. Back
  5. Antenatal, general
  6. Monitoring and Management of Suspected Fetal Growth Restriction (414)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Monitoring and Management of Suspected Fetal Growth Restriction (414)

Warning

Please report any inaccuracies or issues with this guideline using our online form

 

 

Definitions

For the purposes of this guideline the following definitions apply:

Small for gestational age (SGA): Estimated fetal weight (EFW) or abdominal circumference (AC) <10th centile

Fetal growth restriction (FGR):  Where a fetus fails to reach its growth potential as adapted from the Delphi consensus:

Early Onset FGR <32wks

Late onset FGR ≥32wks

EFW or AC <3rd centile

Or Absent umbilical artery end diastolic flow (EDF)

Or EFW/AC <10th centile with at least one of:

  • Umbilical artery pulsatility index >95th centile or absent or reversed EDF
  • Uterine artery pulsatility index >95th centile

EFW <3rd centile

Or At least two of the following:

  • EFW <10th centile
  • EFW crossing ≥50 centiles
  • Umbilical artery pulsatility index >95th centile or absent or reversed EDF

This guideline does not apply to multiple pregnancies or babies with congenital abnormalities.

Estimated fetal weight should be used after 22+0wks as plotted on the Intergrowth chart on Badgernet. Prior to 22+0wks abdominal circumference should be used.

Identifying non-placental causes of FGR

Babies found to have an AC <3rd centile at the time of routine anomaly scan should be referred to a fetal medicine specialist within the unit. Serological screening for cytomegalovirus and toxoplasmosis should be offered along with invasive testing for full karyotype and microarray.

Monitoring of babies found to be SGA

The purpose of monitoring is to identify those babies suspected to have FGR and therefore at greater risk of adverse perinatal outcome. Birth timing balances risk of stillbirth against risk of prematurity including adverse outcomes associated with early term birth (37+0 - 38+6wks).

For babies identified as SGA with no features of FGR suitable surveillance is ultrasound every 2wks for biometry, umbilical artery doppler and liqor volume. In the absence of fetal or maternal compromise birth should be offered at 39+0wks. Examples of fetal or maternal compromise include hypertension, reduced fetal movements, reduced liqor volume or abnormal CTG.

Monitoring of babies identified as early onset FGR

For babies identified as early onset FGR, fetal biometry should be performed every 2wks with weekly liqor volume and umbilical artery doppler. If there is absent or reversed EDF prior to 32+0wks then twice weekly doppler should be performed and birth is indicated if the ductus venosus a wave is absent or reversed.

Cardiotocograph (CTG) can be performed from 26+0wks. If computerised CTG is available then short term variability (STV) should be used to guide birth timing. STV <2.6ms between 26+0 and 28+6wks or <3.0ms between 29+0 and 31+6wks indicates birth should be offered as does the presence of persistent unprovoked decelerations at any gestation. Frequency of CTG monitoring will be determined by the individual circumstances.

Monitoring of babies identified as late onset FGR

For babies identified as late onset FGR, fetal biometry should be performed every 2wks with weekly liqor volume and umbilical artery doppler. Middle cerebral artery doppler performed after 34wks gestation may guide timing of birth but further evidence is awaited on this.  

Frequency of CTG monitoring will depend on individual circumstances. If computerised CTG is available then birth is indicated if STV is <3.5ms between 32+0 and 33+6 or < 4.5ms at gestations >34wks, or in the presence of persistent unprovoked decelerations at any time.

Birth is indicated between 32+0 and 33+6wks if the umbilical artery EDF is reversed. Birth >34wks is indicated if umbilical artery EDF is absent or reversed. Early birth may also be indicated by other evidence of fetal compromise such as decreased liqor volume, maternal hypertension or reduced fetal movements.

If monitoring is reassuring then birth can be offered at 37wks for babies with suspected FGR.

Identifying babies with suboptimal growth

A proportion of babies who are growth restricted will not be SGA, particularly those presenting late in the third trimester.

Evidence of reduced growth velocity or “tailing growth”  is defined as a drop of 50 centiles  on sequential scanning for example a drop from the 70th to the 20th percentile. This should prompt further ultrasound in two weeks with birth offered at 37wks, earlier if there is evidence of fetal or maternal compromise as outlined above. If EFW falls below 10th centile or there are abnormal dopplers then ongoing monitoring and birth timing is as for late onset FGR babies.

Pathway

Algorithm for the monitoring and management of fetal growth restriction

Editorial Information

Last reviewed: 27/02/2024

Next review date: 08/02/2027

Author(s): Roseanna Metcalfe.

Version: 2

Approved By: Maternity Clinical Governance Group

Document Id: 414

Evidence method

Adapted from Saving Baby’s Lives Care Bundle V 3 (2023) and the ISUOG Practice Guideline on diagnosis and management of SGA fetus and FGR (2020)